{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:39Z","timestamp":1740148959823,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AryoGen Co."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12325-020-01611-8","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T05:49:26Z","timestamp":1610430566000},"page":"1290-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Farhad","family":"Gharibdoost","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir-Hossein","family":"Salari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Salesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faegheh","family":"Ebrahimi Chaharom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Mottaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Sahebari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadali","family":"Nazarinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mirfeizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Shakibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Moussavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Karimifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Mowla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-8715","authenticated-orcid":false,"given":"Ahmadreza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"unstructured":"The MeSH Database. https:\/\/www.ncbi.nlm.nih.gov\/mesh\/. Accessed 3 Mar 2020.","key":"1611_CR1"},{"issue":"6","key":"1611_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/annrheumdis-2011-200343","volume":"71","author":"C Bombardier","year":"2012","unstructured":"Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71(6):836\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3899\/jrheum.160103","volume":"43","author":"JA Martikainen","year":"2016","unstructured":"Martikainen JA, Kautiainen H, Rantalaiho V, Puolakka KT. Longterm work productivity costs due to absenteeism and permanent work disability in patients with early rheumatoid arthritis: a nationwide register study of 7831 patients. J Rheumatol. 2016;43(12):2101\u20135.","journal-title":"J Rheumatol"},{"issue":"8","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3899\/jrheum.171195","volume":"45","author":"B Kuriya","year":"2018","unstructured":"Kuriya B, Joshi R, Movahedi M, et al. High disease activity is associated with self-reported depression and predicts persistent depression in early rheumatoid arthritis: results from the Ontario Best Practices Research Initiative. J Rheumatol. 2018;45(8):1101\u20138.","journal-title":"J Rheumatol"},{"issue":"6","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/PSY.0000000000000462","volume":"79","author":"J Euesden","year":"2017","unstructured":"Euesden J, Matcham F, Hotopf M, et al. The relationship between mental health, disease severity, and genetic risk for depression in early rheumatoid arthritis. Psychosom Med. 2017;79(6):638.","journal-title":"Psychosom Med"},{"issue":"8","key":"1611_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00296-016-3493-4","volume":"36","author":"A-R Jamshidi","year":"2016","unstructured":"Jamshidi A-R, Banihashemi AT, Paragomi P, Hasanzadeh M, Barghamdi M, Ghoroghi S. Anxiety and depression in rheumatoid arthritis: an epidemiologic survey and investigation of clinical correlates in Iranian population. Rheumatol Int. 2016;36(8):1119\u201325.","journal-title":"Rheumatol Int"},{"key":"1611_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.comppsych.2015.07.016","volume":"62","author":"D Durmus","year":"2015","unstructured":"Durmus D, Sarisoy G, Alayli G, et al. Psychiatric symptoms in ankylosing spondylitis: their relationship with disease activity, functional capacity, pain and fatigue. Compr Psychiatry. 2015;62:170\u20137.","journal-title":"Compr Psychiatry"},{"issue":"1","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/acr.22577","volume":"68","author":"P Katz","year":"2016","unstructured":"Katz P, Margaretten M, Trupin L, Schmajuk G, Yazdany J, Yelin E. Role of sleep disturbance, depression, obesity, and physical inactivity in fatigue in rheumatoid arthritis. Arthritis Care Res. 2016;68(1):81\u201390.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12891-015-0562-x","volume":"16","author":"M van Vilsteren","year":"2015","unstructured":"van Vilsteren M, Boot CR, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskel Disord. 2015;16(1):107.","journal-title":"BMC Musculoskel Disord"},{"issue":"4","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11136-010-9771-9","volume":"20","author":"H Bodur","year":"2011","unstructured":"Bodur H, Ataman \u015e, Rezvani A, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res. 2011;20(4):543\u20139.","journal-title":"Qual Life Res"},{"issue":"6","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00296-010-1381-x","volume":"31","author":"\u00d6 Baysal","year":"2011","unstructured":"Baysal \u00d6, Durmu\u015f B, Ersoy Y, et al. Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int. 2011;31(6):795\u2013800.","journal-title":"Rheumatol Int"},{"unstructured":"Highlights of Prescribing Information: Enbrel (etanercept). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103795s5569lbl.pdf. Accessed 3 Mar 2020.","key":"1611_CR12"},{"issue":"8","key":"1611_CR13","first-page":"809","volume":"23","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm. 2017;23(8):809\u201314.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/archdermatol.2009.319","volume":"146","author":"V Beyer","year":"2010","unstructured":"Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46\u201354.","journal-title":"Arch Dermatol"},{"unstructured":"Guideline on similar biological medicinal products (CHMP\/437\/04 Rev 1). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 3 Mar 2020.","key":"1611_CR15"},{"issue":"3","key":"1611_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdm345","volume":"19","author":"H Mellstedt","year":"2007","unstructured":"Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2007;19(3):411\u20139.","journal-title":"Ann Oncol"},{"key":"1611_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279.","journal-title":"Front Pharmacol"},{"unstructured":"Generics and Biosimilars Initiative. Biosimilars of etanercept. 2019. http:\/\/gabionline.net\/Biosimilars\/General\/Biosimilars-of-etanercept. Accessed 3 Mar 2020.","key":"1611_CR18"},{"issue":"1","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ph12010014","volume":"12","author":"R Fazel","year":"2019","unstructured":"Fazel R, Guan Y, Vaziri B, et al. Structural and in vitro functional comparability analysis of Altebrel\u2122, a proposed etanercept biosimilar: focus on primary sequence and glycosylation. Pharmaceuticals. 2019;12(1):14.","journal-title":"Pharmaceuticals"},{"doi-asserted-by":"crossref","unstructured":"Azevedo VF, Babini A, Caballero-Uribe CV, Casta\u00f1eda-Hern\u00e1ndez G, Borlenghi C, Jones HE. Practical guidance on biosimilars, with a focus on Latin America: what do rheumatologists need to know? J Clin Rheumatol. 2019;25(2):91.","key":"1611_CR20","DOI":"10.1097\/RHU.0000000000000881"},{"issue":"2","key":"1611_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"V Suvarna","year":"2010","unstructured":"Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1(2):57.","journal-title":"Perspect Clin Res"},{"unstructured":"WHO. The use of the WHO-UMC system for standardised case causality assessment https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf. Accessed 3 Mar 2020.","key":"1611_CR22"},{"unstructured":"FDA. What is a serious adverse event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 3 Mar 2020.","key":"1611_CR23"},{"issue":"10","key":"1611_CR24","first-page":"2016","volume":"32","author":"GA Wells","year":"2005","unstructured":"Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol. 2005;32(10):2016\u201324.","journal-title":"J Rheumatol"},{"issue":"1","key":"1611_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13075-016-1151-6","volume":"18","author":"E Nikiphorou","year":"2016","unstructured":"Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18(1):251.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999;130(6):478\u201386.","journal-title":"Ann Intern Med"},{"issue":"22","key":"1611_CR27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586\u201393.","journal-title":"N Engl J Med"},{"issue":"4","key":"1611_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264\u201372.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1611_CR30","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1611_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"4","key":"1611_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PTS.0b013e3181fd1697","volume":"6","author":"DJ Noble","year":"2010","unstructured":"Noble DJ, Pronovost PJ. Underreporting of patient safety incidents reduces health care\u2019s ability to quantify and accurately measure harm reduction. J Patient Saf. 2010;6(4):247\u201350.","journal-title":"J Patient Saf"},{"issue":"7","key":"1611_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3899\/jrheum.100698","volume":"38","author":"DD Gladman","year":"2011","unstructured":"Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol. 2011;38(7):1355\u201362.","journal-title":"J Rheumatol"},{"issue":"6","key":"1611_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00393-018-0536-0","volume":"78","author":"M Gaubitz","year":"2019","unstructured":"Gaubitz M, Lippe R, G\u00f6ttl K, et al. Etanercept in der klinischen Routinebehandlung von Patienten mit rheumatoider Arthritis. Z Rheumatol. 2019;78(6):552\u20138.","journal-title":"Z Rheumatol"},{"issue":"4","key":"1611_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/s10165-010-0406-3","volume":"21","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343\u201351.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1611_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/BOR.0b013e3283521c64","volume":"24","author":"M Her","year":"2012","unstructured":"Her M, Kavanaugh A. Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):327\u201334.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"1611_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/rheumatology\/keh140","volume":"43","author":"V Strand","year":"2004","unstructured":"Strand V, Cohen S, Crawford B, Smolen J, Scott D. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology. 2004;43(5):640\u20137.","journal-title":"Rheumatology"},{"issue":"01","key":"1611_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2008.102509","volume":"69","author":"J Kekow","year":"2010","unstructured":"Kekow J, Moots R, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69(01):222\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1611_CR39","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s10067-017-3757-8","volume":"36","author":"M Gaubitz","year":"2017","unstructured":"Gaubitz M, G\u00f6ttl K-H, Behmer O, Lippe R, Meng T, L\u00f6schmann P-A. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. Clin Rheumatol. 2017;36(9):1989\u201396.","journal-title":"Clin Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01611-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:02:57Z","timestamp":1724306577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01611-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01611-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"2 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}